KR101540838B1 - 방사선치료 효능을 강화시키는 ｍｅｔ 억제제 - Google Patents

방사선치료 효능을 강화시키는 ｍｅｔ 억제제 Download PDF

Info

Publication number
KR101540838B1
KR101540838B1 KR1020120025311A KR20120025311A KR101540838B1 KR 101540838 B1 KR101540838 B1 KR 101540838B1 KR 1020120025311 A KR1020120025311 A KR 1020120025311A KR 20120025311 A KR20120025311 A KR 20120025311A KR 101540838 B1 KR101540838 B1 KR 101540838B1
Authority
KR
South Korea
Prior art keywords
met
met inhibitor
administered
polynucleotide
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020120025311A
Other languages
English (en)
Korean (ko)
Other versions
KR20120106582A (ko
Inventor
카를라 보카치오
파올로 마리아 코모글리오
피오렐라 페트론젤리
리타 데 산티스
Original Assignee
메테레시스 트랜스레이셔날 리서치 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메테레시스 트랜스레이셔날 리서치 에스.에이. filed Critical 메테레시스 트랜스레이셔날 리서치 에스.에이.
Publication of KR20120106582A publication Critical patent/KR20120106582A/ko
Application granted granted Critical
Publication of KR101540838B1 publication Critical patent/KR101540838B1/ko
Assigned to 메티스 프리시젼 메디슨 에스비 에스.알.엘. reassignment 메티스 프리시젼 메디슨 에스비 에스.알.엘. 권리의 전부이전등록 Assignors: 메테레시스 트랜스레이셔날 리서치 에스.에이.
Assigned to 버티칼 바이오 아게 reassignment 버티칼 바이오 아게 권리의 전부이전등록 Assignors: 메티스 프리시젼 메디슨 에스비 에스.알.엘.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020120025311A 2011-03-18 2012-03-13 방사선치료 효능을 강화시키는 ｍｅｔ 억제제 Active KR101540838B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11158861.2A EP2500036B1 (en) 2011-03-18 2011-03-18 MET inhibitors for enhancing radiotherapy efficacy
EP11158861.2 2011-03-18

Publications (2)

Publication Number Publication Date
KR20120106582A KR20120106582A (ko) 2012-09-26
KR101540838B1 true KR101540838B1 (ko) 2015-08-06

Family

ID=44260211

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120025311A Active KR101540838B1 (ko) 2011-03-18 2012-03-13 방사선치료 효능을 강화시키는 ｍｅｔ 억제제

Country Status (22)

Country Link
US (1) US20120237524A1 (https=)
EP (1) EP2500036B1 (https=)
JP (1) JP5671487B2 (https=)
KR (1) KR101540838B1 (https=)
CN (1) CN102688491A (https=)
AU (1) AU2012201303B2 (https=)
BR (1) BR102012006063B1 (https=)
CA (1) CA2769991C (https=)
CY (1) CY1115374T1 (https=)
DK (1) DK2500036T3 (https=)
EA (1) EA028590B1 (https=)
ES (1) ES2489475T3 (https=)
HR (1) HRP20140729T1 (https=)
IL (1) IL218293A (https=)
MX (1) MX2012003084A (https=)
PL (1) PL2500036T3 (https=)
PT (1) PT2500036E (https=)
RS (1) RS53468B (https=)
SG (1) SG184637A1 (https=)
SI (1) SI2500036T1 (https=)
SM (1) SMT201400106B (https=)
ZA (1) ZA201201992B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN110320365B (zh) * 2019-07-06 2022-07-22 湖南莱拓福生物科技有限公司 NF-κB RelA/p65蛋白位点特异性磷酸化诊断试剂盒
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
TWI476206B (zh) * 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
ES2368864T3 (es) * 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
EP2019116A1 (en) * 2007-07-26 2009-01-28 Helmholtz-Zentrum für Infektionsforschung GmbH Inhibitor of the met-receptor and its use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Maria Prat 등. Journal of Cell Science. Vol. 111, No. 2, 페이지 237-247 (1998.)
논문 1 : J. Biol. Chem.

Also Published As

Publication number Publication date
SG184637A1 (en) 2012-10-30
AU2012201303A1 (en) 2012-10-04
AU2012201303B2 (en) 2013-11-07
EP2500036A1 (en) 2012-09-19
JP2012196206A (ja) 2012-10-18
EA028590B1 (ru) 2017-12-29
JP5671487B2 (ja) 2015-02-18
SI2500036T1 (sl) 2014-09-30
HRP20140729T1 (hr) 2014-08-29
HK1174539A1 (en) 2013-06-14
DK2500036T3 (da) 2014-08-04
CA2769991C (en) 2018-05-15
PL2500036T3 (pl) 2014-10-31
ES2489475T3 (es) 2014-09-02
CA2769991A1 (en) 2012-09-18
RS53468B (sr) 2014-12-31
CY1115374T1 (el) 2017-01-04
CN102688491A (zh) 2012-09-26
BR102012006063A8 (pt) 2022-11-08
MX2012003084A (es) 2012-09-17
IL218293A0 (en) 2012-07-31
PT2500036E (pt) 2014-08-25
EA201200329A3 (ru) 2013-01-30
US20120237524A1 (en) 2012-09-20
BR102012006063B1 (pt) 2023-03-07
ZA201201992B (en) 2015-05-27
KR20120106582A (ko) 2012-09-26
SMT201400106B (it) 2014-11-10
EA201200329A2 (ru) 2012-09-28
EP2500036B1 (en) 2014-05-07
BR102012006063A2 (pt) 2021-11-16
IL218293A (en) 2016-06-30

Similar Documents

Publication Publication Date Title
KR101540838B1 (ko) 방사선치료 효능을 강화시키는 ｍｅｔ 억제제
CN108136001B (zh) 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
US8080533B2 (en) Hypoxia induced mitogenic factor
JP2023162213A (ja) がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤
AU2009299744B2 (en) Inhibition of PLGF to treat Philadelphia chromosome positive leukemia
CN112543809A (zh) 包含C/EBPα saRNA的组合疗法
Sangaletti et al. Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis
EP3016682A1 (en) Methods for treating cancer
AU2020103404A4 (en) Medicinal composition comprising a non-coding RNA molecule and an antibody targeting a tumor antigen
WO2022174781A1 (zh) 多结构域融合蛋白及其应用
US20120121589A1 (en) Modified egfr ectodomain
RU2830698C1 (ru) Соответствующая мишень для лечения фиброзирующих заболеваний и ее применение
HK1174539B (en) Met inhibitors for enhancing radiotherapy efficacy
Rosa Doctorate Program in Molecular Oncology and Endocrinology Doctorate School in Molecular Medicine
HK1253276B (en) Treatment of cancer using inhibitors of tgf-beta and pd-1

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20180712

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190717

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 11